Silver nanoparticles (AgNPs) have emerged as promising agents in cancer diagnostics and/or therapy, demonstrating a lot of possible pharmacological actions. However, understanding the pharmacokinetics and safety profiles of nanoparticles, which is crucial for their clinical application, still raises many questions. Studies indicate that AgNPs can accumulate in tumour tissues, improving drug delivery and specificity. However, their interaction with biological systems necessitates thorough safety evaluations. Classical methods for assessing AgNPs’ safety include cytotoxicity assays, genotoxicity tests, and histopathological examinations. However, novel techniques are emerging, such as advanced imaging and biomarker analysis, offering more precise toxicity assessments. Prediction models, including computational simulations and in silico analyses, are being developed to forecast AgNPs’ toxicity profiles. These models aim to reduce reliance on animal testing and expedite the evaluation process. To mitigate potential risks associated with nanoparticle-based therapies, strategies such as surface modification, controlled release systems, and targeted delivery are being explored. These methods aim to enhance therapeutic efficacy while minimizing adverse effects. The main aim of this review article is to describe AgNPs from the point of view of their pharmacokinetic/toxicokinetic profile in the light of modern knowledge. Special attention will be given to novel methods for assessing the safety and toxicity profiles of AgNPs, providing insights into their interactions with cancer therapies and their potential clinical applications.

The purpose of this narrative review is to critically appraise recent advances in sports injury rehabilitation—primarily focusing on biopsychosocial (BPS) approaches alongside emerging technological innovations—and identify current gaps and future directions. A literature search was conducted in PubMed, Scopus, and Web of Science for the years 2018–2024. Eligible records were English-language, human studies comprising systematic reviews, clinical trials, and translational investigations on wearable sensors, artificial intelligence (AI), virtual reality (VR), regenerative therapies (platelet-rich plasma [PRP], bone marrow aspirate concentrate [BMAC], stem cells, and prolotherapy), and BPS rehabilitation models; single-patient case reports, editorials, and non-scholarly sources were excluded. The synthesis yielded four themes: (1) BPS implementation remains underutilised owing to a lack of validated tools, variable provider readiness, and system-level barriers; (2) wearables and AI can enhance real-time monitoring and risk stratification but are limited by data heterogeneity, non-standardised pipelines, and sparse external validation; (3) VR/gamification improves engagement and task-specific practice, but evidence is dominated by pilot or laboratory studies with scarce longitudinal follow-up data; and (4) regenerative interventions show mechanistic promise, but conclusions are constrained by methodological variability and regulatory hurdles. Conclusions: BPS perspectives and emerging technologies have genuine potential to improve outcomes, but translation to practice hinges on (1) pragmatic or hybrid effectiveness–implementation trials, (2) standardisation of data and intervention protocols (including core outcome sets and effect-size reporting), and (3) integration of psychological and social assessment into routine pathways supported by provider training and interoperable digital capture.

Background: The minimum clinically important difference (MCID) for the St George’s Respiratory Questionnaire (SGRQ) is debated in chronic obstructive pulmonary disease (COPD) quality-of-life (QoL) assessments. This study aimed to determine whether there is a difference in predictors of clinically significant improvement between the traditional (value of 4) and newly proposed MCID SGRQ (value of 7) after climatic rehabilitation treatment. Climatic rehabilitation treatment consists of two main parts: climatotherapy, which typically involves the controlled exposure of individuals to natural environmental elements, and climatic rehabilitation, which includes other therapeutic factors such as physical activities as well as educating the patient to change their lifestyle. Methods: This study included 90 consecutive patients diagnosed with COPD who underwent structured complex pulmonary rehabilitation in High Tatras, part of the Carpathian Mountains. The examination before and after treatment included spirometry, QoL assessment using the SGRQ, 6 min walk test (6-MWT), and the Borg, Beck and Zung scale. Results: Patients showed statistically significant improvement after the intervention in FEV1, FEV1/FVC, 6-MWT, (p < 0.001), anxiety scores, depression, and improvement in dyspnoea both before and after the 6-MWT (p < 0.001). For both MCID for SGRQ levels 4 and 7, we confirmed the same predictors of clinical improvement for bronchial obstruction grade (spirometry) and exercise capacity (6-MWT), for quality of life in activity score and total score. Conclusion. The results suggest that both the proposed MCID for SGRQ values could be sufficient to assess the clinical significance of the achieved change in health status when assessing the need for pulmonary rehabilitation comprising climatotherapy in patients with COPD.

Article: Evidence-based position paper on the professional practice of Physical and Rehabilitation Medicine for persons with cerebral palsy. The European PRM position (UEMS PRM section) - European Journal of Physical and Rehabilitation Medicine 2021 December;57(6):1020-35 - Minerva Medica - Journals

Background and Objectives: Post-COVID-19 condition (PCC, long COVID) is associated with persistent symptoms and marked reductions in health-related quality of life (HRQoL), but real-world data on rehabilitation and everyday functioning remain limited. Materials and Methods: In a cross-sectional online survey conducted between 15 April and 15 May 2024, we analysed 406 adults (308 women; mean age 36.0 ± 12.1 years) with ongoing post-COVID symptoms recruited from two moderator-supervised support communities. The questionnaire included sociodemographic and clinical items, the 36-Item Short Form Health Survey (SF-36) and the Post-COVID-19 Functional Status (PCFS) scale. Participants indicated whether they had completed any form of rehabilitation targeting post-COVID problems (yes/no). Group differences were examined using Welch’s t-test, Mann–Whitney U and χ² tests, as appropriate. Multiple linear regression models with Bonferroni correction were used to explore associations between rehabilitation status, age, sex, symptom duration and outcomes. Results: Overall, 182 respondents (44.8%) reported rehabilitation and 224 (55.2%) did not. The groups did not differ significantly in age, sex distribution, BMI, number of infections, symptom duration or hospitalisation history. Most SF-36 domains, component summaries and PCFS differed significantly between groups, with small-to-large effects favouring respondents who reported rehabilitation. The largest effect sizes were observed for Vitality and Mental Health, whereas Physical Functioning showed no clear difference. In multivariable models, older age and longer symptom duration were consistently associated with poorer HRQoL, while rehabilitation status remained a robust correlate of better scores in several SF-36 domains, both component summaries, perceived health, and lower PCFS grades after correction for multiple testing. Conclusions: Although the cross-sectional design, self-reported data and non-standardised rehabilitation exposure preclude causal inference, the findings highlight the substantial HRQoL and functional burden of long COVID and suggest that, within a symptomatic population, reported completion of rehabilitation is positively associated with multiple aspects of everyday health and functioning.